Effect of Hydroquinone + Tretinoin + Corticosteroid on Melasma

Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24-week double-blind prospective randomized controlled trial (2023)

Safety and efficacy of topical metformin 30% cream versus triple combination cream (Kligman's formula) in treating melasma: A randomized controlled study (2022)

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial (2021)

Topical metformin in the treatment of melasma: A preliminary clinical trial (2020)

Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin (2019)

Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination (2014)

Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity (2012)

Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma (2010)

A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream (2009)

A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma (2008)

A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma (2007)

Community-based trial of a triple-combination agent for the treatment of facial melasma (2006)

Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma (2005)

Efficacy and safety of a new triple-combination agent for the treatment of facial melasma (2003)